Journal of Immunology Research

Research Article

Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies

Table 1

Main clinical and laboratory data in 60 patients with polyneuropathy, IgM gammopathy, and anti-MAG antibodies.
PatientAgeGenderDuration of symptoms (months)Clinical pictureLimb involvementNCS findingsType of gammopathyAnti-MAG titre (BTU)DIFIIFOther antibodiesEM pattern
174M84SMD, Sy, 4LMAGMGUS26 870IgM, C3dIgM, C3dNegWML
269F36AD, Sy, 4LMAGMGUS61 186IgM, C3dIgM, C3dNegCIDP
363F24AD, Sy, 4MMAGSpleen lymphoma23 800NDIgM, C3dNegND
464F18SD, Sy, 4LMAGMGUS15 000IgM, C3dIgM, C3dNegCIDP
576M12AD, Sy, 4LMAGMGUS70 000NDNDNegND
675M204SMD, Sy, LLMAGWaldenström57 237IgMIgM, C3dNegWML
766M108SMD, Sy, 4LSAMGUS48 584NegNegNegWML
878M108AD, Sy, 4LMAGHairy cell leukemia14 125NegNegNegWML
973M24SD, Sy, LLMAGMGUS34 621IgM, C3dIgM, C3dNegWML
1074F36SD, Sy, 4LMAGMGUS66 970NDNDNegND
1175M60SMD, Sy, LLMAGChronic myelomonocytic leukemia1 312NegIgMSGPG/GangCIDP
1270F24SMD, Sy, LLNDMGUS70 000NDNDSGPGWML
1357M12SD, Sy, LLMAGMGUSPos (WB)NDNDNegWML
1456M3SD, Sy, LLMAGMGUS12 000NDNDNegND
1561M18SMD, Sy, LLMAGMGUS20 059NegIgMGang/SulfCIDP
1666M12SD, Sy, LLNDMGUS55 127NegNDNegWML
1769F36AD, Sy, LLMAGMGUS70 000NDNDNDND
1874M24SMD, As, LLMAGMGUS1 111NDNDSGPGWML
1979M9SMP, As, LLMAGMGUS19 127IgM, C3dIgM, C3dSGPGWML
2060M192SMD, Sy, 4LMAGMGUS76 210NegNegGangWML
2157M12SMD, As, 4LMAGMGUS70 000NegIgMNegCIDP
2246M12SMD, Sy, LLNDMGUS23 915NegIgMSGPG/GangWML
2358M11SD, As, ULMAGMGUS1 794IgM, C3dIgM, C3dSGPGWML
2466M12SMD, Sy, LLMAGMGUS42 346NDIgMNegND
2578M12SMD, Sy, LLSAWaldenström97 194IgMIgMNegWML
2660F24SD, Sy, LLMAGChronic lymphocytic leukemia70 000IgM, C3dNegSGPGWML (B cell inf)
2769M96AD, Sy, LLMAGMGUSPos (WB)IgMIgMNegWML
2873M12AD, As, LLMAGMGUS34 546IgMIgMNegWML
2972M24SMD, As, LLMAGMGUS8 363C3dIgM, C3dSGPGWML
3064M24SMD, Sy, 4LMAGMGUS70 000NDNDSGPG/GangWML
3152M72SMD, Sy, 4LMAGMGUS27 721NegIgM, C3dNegWML
3275F12SD, Sy, 4LMAGMGUSPos (WB)IgMNegNegWML
3367F6SD, Sy, LLMAGMGUS35 971NDNDNegND
3452M24SMD, Sy, LLMAGMGUS16 272NDIgM, C3dNegND
3557F96SMD, Sy, LLMAGMGUS70 000IgM, C3dIgMSGPGWML
3661M2SMD, Sy, LLMAGMGUSPos (WB)NDNDSGPG/GangWML
3757F24SD, Sy, 4LMAGMGUS70 000NDNDNegND
3878M72SD, Sy, LLMAGMGUS13 395IgM, C3dIgM, C3dNegWML
3979F12SD, Sy, LLMAGMGUS70 000NegIgMNegWML
4073M144SMD, Sy, LLMAGMGUS23 198NDNDNegND
4171M12SD, As, LLMAGMGUS4 165NDNDNDWML
4287M24SMD, Sy, 4LMAGB cell lymphoma70 000NegIgMNegWML
4356F6SD, Sy, LLNDMGUS56 644NDIgMSGPGND
4450M3SMD, Sy, 4LCIDPMGUS61 960NDNDNegND
4558M12SMD, As, LLCIDPMGUS3 008NegNegNegCIDP
4677M48SMD, As, LLCIDPWaldenström16 958C3dNegNegCIDP
4767M18SMD, As, 4LCIDPMGUS2 636NegC3dNegCIDP
4877M3AD, Sy, LLCIDPMGUS4 342NegNegNegCIDP
4965M48AD, Sy, 4LCIDPMGUS9 224NDNegNegND
5050M12AD, Sy, 4LCIDPMGUS5 177NegNegSGPGCIDP
5182M6SMD, Sy, LLCIDPWaldenström70 000NegC3dNegCIDP
5278M12SMD, Sy, LLCIDPNHML26 058IgM, C3dNegNegWML
5356M4SMD, As, 4LCIDPMGUS6351NegNegNegCIDP
5475F15SMP, Sy, LLCIDPMGUS17 530NegNegNegCIDP
5549M12SD, Sy, 4LCIDPMGUS5328NegNegNegCIDP
5647M24SD, As, 4LCIDPMGUS62 978NDNegNegND
5768M8SMD, Sy, 4LCIDPMGUS8 300NegNegNegCIDP
5883F18SMD, Sy, 4LCIDPMGUS36 726NDIgM, C3dNegND
5969F48AD, As, LLCIDPMGUS10 064NDNegNegND
6077F12SMD, As, LLCIDPMGUS2884NegNegNegCIDP
A: prominent ataxia, As: asymmetric, D: distal distribution, DIF: direct immunofluorescence, F: female, Gang: ganglioside, IIF: indirect immunofluorescence, M: male, LL: lower limb predominance, MGUS: monoclonal gammopathy of undetermined significance, Neg: negative, NHML: non Hodgkin’s malignant lymphoma, S: pure sensory neuropathy without ataxia, Sy: symmetrical, SA: sensory axonal polyneuropathy, SGPG: sulfate-3-glucuronyl paragloboside, SM: sensory and motor polyneuropathy, UL: upper limb predominance, 4L: four limb involvement.